Genmab's successful CEO dismisses retirement plans

Wednesday, Genmab CEO Jan van de Winkel presented yet another guidance upgrade. Even though he has passed 60 years of age, he underscores his intention to remain on board with the company for many years yet.
Photo: PR / Genmab
Photo: PR / Genmab
BY ANDREAS LØNSTRUP, TRANSLATED BY DANIEL FRANK CHRISTENSEN

This Wednesday was in many ways "just another day at the office" for Genmab Chief Executive Jan van de Winkel.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading